Label claims on a tranexamic acid and kojic acid body wash must stay within the cosmetic definition in your target market — meaning they describe an effect on the appearance of skin, not a treatment or cure for a disease or condition. Getting this boundary right is one of the most important legal steps before launch.
Permitted cosmetic claims in the United States (under FDA guidance) include language like: "visibly brightens skin," "evens skin tone over time," "reduces the appearance of dark spots," "improves radiance," "for a more luminous look," and "leaves skin looking more uniform." These claims are about appearance and perception, not mechanism.
Claims that cross into drug territory — and that the FDA has historically flagged — include: "treats hyperpigmentation," "inhibits melanin production" (when framed as a drug mechanism), "lightens age spots" in a therapeutic context, "acts like hydroquinone," or anything suggesting the product alters skin function at a biological level in a lasting, structural way. The FDA's OTC drug monograph for skin-bleaching agents (which covered hydroquinone) is now effectively withdrawn, making the regulatory space somewhat fluid, but the cosmetic-vs-drug line remains.
In the EU, claims must be substantiated with evidence and must not mislead consumers. The EU's Common Criteria for cosmetic claims (Regulation EC 655/2013) require that any claim be truthful, supported by adequate evidence, and not imply a medical effect. The phrase "skin-whitening" is used and permitted in EU markets but must be backed by efficacy data (typically in vitro or in vivo studies).
For body wash specifically, claims must account for the rinse-off nature of the product. Claiming "deep pigmentation correction" on a wash-off product is difficult to substantiate because active contact time is short. A cosmetic chemist can recommend penetration enhancers (glycols, certain esters) to improve active delivery during limited contact time, and some manufacturers have supporting in vitro data for these systems.
Transexamic acid is a relatively newer cosmetic active with less regulatory history than kojic acid. It is not FDA-classified as a drug in topical rinse-off use, and claims around "brightening" and "tone-evening" are broadly accepted. Some brands use the ingredient name directly in marketing — "formulated with tranexamic acid" — which is permissible and popular because consumer recognition of the ingredient is growing rapidly.
Document your claim substantiation in a regulatory dossier before you launch. This includes in vitro or consumer-use study data, the safety assessment, and a legal review of every claim on your label and website. Retailers like Target and Ulta increasingly ask for this documentation during vendor onboarding.
Ingredients in this answer: Tranexamic Acid · Kojic Acid
Read the full guide on Private Label Tranexamic & Kojic Acid Body Wash Low MOQ →